Related Experiment Video
Updated: Feb 10, 2026

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
Published on: December 27, 2010
Benefits and Risks of Statin Therapy in the HIV-Infected Population
Mosepele Mosepele1,2,3, Onkabetse J Molefe-Baikai4, Steven K Grinspoon5
1Department of Internal Medicine, Faculty of Medicine, University of Botswana, Gaborone, Botswana. mosepelemosepele@gmail.com.
Insights
HIV patients have a higher risk of cardiovascular disease (CVD). Statins are underutilized in this population, but pitavastatin shows promise due to fewer drug interactions with antiretroviral therapy (ART).
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- HIV infection significantly increases cardiovascular disease (CVD) risk (1.5-2x) compared to HIV-uninfected individuals.
- Cardiovascular disease (CVD) prevention in HIV patients is crucial due to increased risk factors.
Purpose of the Study:
- To review the role of statin therapy in reducing CVD risk in HIV-infected patients on antiretroviral therapy (ART).
- To summarize recent findings (last 5 years) on statin use for CVD risk reduction in HIV populations.
Main Methods:
- Review of recent literature (within 5 years) on statin therapy and CVD risk in HIV-infected patients.
- Analysis of clinical guidelines and studies on statin utilization and efficacy in HIV populations.
Main Results:
- Statins are recommended for CVD risk reduction in HIV patients, extrapolated from general population guidelines, but are underprescribed.
- Rosuvastatin and atorvastatin are commonly studied, offering potent lipid-lowering and favorable pleiotropic effects.
- Pitavastatin demonstrates comparable lipid-lowering with fewer adverse drug interactions with ART and no impact on glucose metabolism, making it a preferred agent.
Conclusions:
- Statins are underutilized for CVD prevention in HIV-infected patients despite established guidelines.
- Pitavastatin emerges as a promising option due to its favorable interaction profile with ART.
- Ongoing trials will further define the role of statin therapy, including for patients not meeting current guideline criteria.
Purpose Of Review:
HIV-infected patients face an increased risk for cardiovascular disease (CVD), estimated at 1.5- to 2-fold as compared to HIV-uninfected persons. This review provides a recent (within preceding 5 years) summary of the role of statin therapy and associated role in CVD risk reduction among HIV-infected patients on anti-retroviral therapy.
Recent Findings:
Statins remain the preferred agents for reducing risk for CVD among HIV-infected populations based on guidance extrapolated from general population (HIV-uninfected) cholesterol treatment guidelines across different settings globally. However, HIV-infected patients are consistently under prescribed statin therapy when compared to their HIV-uninfected counterparts. The most commonly studied statins in clinical care and small randomized and cohort studies have been rosuvastatin and atorvastatin. Both agents are preferred for their potent lipid-lowering effects and their favorable or neutral pleotropic effects on chronic inflammation, renal function, and hepatic steatosis among others. However, growing experience with the newer glucuronidated pitavastatin suggests that this agent has virtually no adverse drug interactions with ART or effects on glucose metabolism-all marked additional benefits when compared with rosuvastatin and atorvastatin while maintaining comparable anti-lipid effects. Pitavastatin is therefore the statin of choice for the ongoing largest trial (6500 participants) to test the benefits of statin therapy among HIV-infected adults. Statins are underutilized in the prevention of CVD in HIV-infected populations based on criteria in established cholesterol guidelines. There is a potential role for statin therapy for HIV-infected patients who do not meet guideline criteria which will be further delineated through ongoing clinical trials.
More Related Videos
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Conservation of Small Populations
Benefits of Self-Esteem
What is Population Genetics?
Population Growth
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

